SRT3

218.65

-2.52%↓

ORNBV.FI

68.75

+0.36%↑

PHMA

95.6

-1.49%↓

DRW3

91.2

+1%↑

SRT3

218.65

-2.52%↓

ORNBV.FI

68.75

+0.36%↑

PHMA

95.6

-1.49%↓

DRW3

91.2

+1%↑

SRT3

218.65

-2.52%↓

ORNBV.FI

68.75

+0.36%↑

PHMA

95.6

-1.49%↓

DRW3

91.2

+1%↑

SRT3

218.65

-2.52%↓

ORNBV.FI

68.75

+0.36%↑

PHMA

95.6

-1.49%↓

DRW3

91.2

+1%↑

SRT3

218.65

-2.52%↓

ORNBV.FI

68.75

+0.36%↑

PHMA

95.6

-1.49%↓

DRW3

91.2

+1%↑

Home・Akciju saraksts・Sanofi SA

Search

Sanofi SA

Atvērts

SektorsVeselības aprūpe

72.85 -0.68

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

72.775

Max

74.4

Galvenie mērījumi
By Trading Economics
Ienākumi	-394M 1.6B
Pārdošana	-12B 11B
P/E Sektora vidējais	20.158 49.8
EPS	1.34
Peļņas marža	14.354
Darbinieki	74,846
EBITDA	1.5B 2.7B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+25.23% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 30. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-5.1B 94B
Iepriekšējā atvēršanas cena	73.53
Iepriekšējā slēgšanas cena	72.85

Ziņu noskaņojums

By Acuity

43%

57%

141 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

91.3 / 96.1 Atbalsts un pretestība

Sanofi SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. apr. 09:03 UTC

Peļņas

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

2026. g. 29. apr. 05:27 UTC

Peļņas

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

2026. g. 23. apr. 06:12 UTC

Peļņas

Sanofi Posts Higher Sales Amid Leadership Transition

2026. g. 7. maijs 06:47 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

2026. g. 1. maijs 06:14 UTC

Iegādes, apvienošanās, pārņemšana

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

2026. g. 1. maijs 06:13 UTC

Iegādes, apvienošanās, pārņemšana

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

2026. g. 1. maijs 06:12 UTC

Iegādes, apvienošanās, pārņemšana

Santander UK Financed Deal From Existing Cash Resources

2026. g. 1. maijs 06:08 UTC

Iegādes, apvienošanās, pārņemšana

Santander UK Announced Key Terms of Deal July 2025

2026. g. 1. maijs 06:03 UTC

Iegādes, apvienošanās, pārņemšana

Santander UK Buys TSB Banking for GBP2.65B

2026. g. 1. maijs 06:02 UTC

Iegādes, apvienošanās, pārņemšana

Santander UK Buys TSB Banking Group

2026. g. 29. apr. 12:01 UTC

Peļņas

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

2026. g. 29. apr. 06:27 UTC

Tirgus saruna

Peļņas

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

2026. g. 29. apr. 04:55 UTC

Peļņas

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

2026. g. 29. apr. 04:55 UTC

Peļņas

Santander 1Q Loan Loss Provisions EUR3.225B

2026. g. 29. apr. 04:54 UTC

Peļņas

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

2026. g. 29. apr. 04:54 UTC

Peļņas

Santander 1Q Operating Expenses EUR6.48B

2026. g. 29. apr. 04:52 UTC

Peļņas

Santander Backs 2028 View

2026. g. 29. apr. 04:52 UTC

Peļņas

Santander Backs 2026 View

2026. g. 29. apr. 04:52 UTC

Peļņas

Santander 1Q Underlying RoTE 15.2%

2026. g. 29. apr. 04:51 UTC

Peļņas

Santander End-1Q CET1 Ratio 14.4%

2026. g. 29. apr. 04:51 UTC

Peļņas

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

2026. g. 29. apr. 04:51 UTC

Peļņas

Santander 1Q Net Interest Income EUR11.02B

2026. g. 29. apr. 04:50 UTC

Peļņas

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

2026. g. 29. apr. 04:50 UTC

Peļņas

Santander 1Q Underlying Pft EUR3.56B

2026. g. 29. apr. 04:49 UTC

Peļņas

Santander 1Q Net Pft EUR5.455B

2026. g. 29. apr. 04:49 UTC

Peļņas

Analysts Saw Santander 1Q Rev EUR15.00B

2026. g. 29. apr. 04:49 UTC

Peļņas

Santander 1Q Rev EUR15.14B

2026. g. 27. apr. 09:32 UTC

Tirgus saruna

Peļņas

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

2026. g. 27. apr. 09:19 UTC

Tirgus saruna

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

2026. g. 23. apr. 05:34 UTC

Peļņas

Sanofi: 2026 Expectations Are at Constant Exchange Rates

Salīdzinājums

Cenas izmaiņa

Sanofi SA Prognoze

Cenas mērķis

By TipRanks

25.23% augšup

Prognoze 12 mēnešiem

Vidējais 93.471 EUR 25.23%

Augstākais 106.742 EUR

Zemākais 79.807 EUR

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sanofi SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

4

Pirkt

6

Turēt

0

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Sanofi SA — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

91.3 / 96.1Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

141 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Citi krājumi no sektora

SRT3

Sartorius AG

218.65

ORNBV.FI

Orion Oyj (Class B)

68.75

PHMA

Pharma Mar SA

95.6

DRW3

Draegerwerk AG & Co KGaA- PREF

91.2

Live chat